ADDITIONAL COSTS RELATED TO ORAL JANUS KINASE INHIBITOR USE IN ATOPIC DERMATITIS

被引：0
|
作者：
Robinson, Stephen [1 ]
Kallala, Rami [1 ]
Jo-Hansen, Christian Dall [2 ]
Panek, Malgorzata [3 ]
Nikodem, Mateusz [3 ]
Chudzik, Kamila [3 ]
Damentko, Magdalena [4 ]
Brandi, Henrik [5 ]
机构：
[1] Leo Pharma UK, Maidenhead, Berks, England
[2] Leo Pharma AS, Copenhagen, Denmark
[3] Putnam PHMR, Krakow, Poland
[4] Putnam PHMR, Warsaw, Poland
[5] Leopharma AS, Copenhagen, Denmark
来源：
ACTA DERMATO-VENEREOLOGICA | 2023年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P5.6
引用
收藏
页码：33 / 34
页数：2
相关论文
共 50 条
  • [21] The suitability of treating atopic dermatitis with Janus kinase inhibitors
    Narla, Shanthi
    Silverberg, Jonathan, I
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2022, 18 (05) : 439 - 459
  • [22] The role of Janus kinase signaling in the pathology of atopic dermatitis
    Guttman-Yassky, Emma
    Irvine, Alan D.
    Brunner, Patrick M.
    Kim, Brian S.
    Boguniewicz, Mark
    Parmentier, Julie
    Platt, Andrew M.
    Kabashima, Kenji
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 152 (06) : 1394 - 1404
  • [23] Treatment of atopic dermatitis with biologics and Janus kinase inhibitors
    Thyssen, Jacob P.
    Thomsen, Simon F.
    LANCET, 2021, 397 (10290): : 2126 - 2128
  • [24] Oclacitinib, a novel Janus kinase inhibitor for the treatment of atopic dermatitis and other case of pruritus in dogs
    Akos, Jerzsele
    Dora, Kovacs
    Zoltan, Somogyi
    MAGYAR ALLATORVOSOK LAPJA, 2017, 139 (09) : 545 - 552
  • [25] Refractory cutaneous lichen amyloidosis coexisting with atopic dermatitis responds to the Janus Kinase inhibitor baricitinib
    Xia, Dengmei
    Xiao, Yue
    Li, Mengmeng
    Li, Wei
    DERMATOLOGIC THERAPY, 2022, 35 (09)
  • [26] Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model
    Yamamoto, Yasuo
    Otsuka, Atsushi
    Nakashima, Chisa
    Ishida, Yoshihiro
    Honda, Tetsuya
    Egawa, Gyohei
    Amano, Wataru
    Usui, Kenji
    Hamada, Yuji
    Wada, Masashi
    Tanimoto, Atsuo
    Konishi, Noriko
    Hayashi, Mikio
    Matsushita, Mutsuyoshi
    Kabashima, Kenji
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2020, 97 (02) : 161 - 164
  • [27] Dose flexibility of oral Janus kinase inhibitors for long-term control of atopic dermatitis
    Ebata, Toshiya
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (02) : 165 - 165
  • [28] Predictors of maintenance of response in patients with moderate to severe atopic dermatitis after oral Janus kinase 1 selective inhibitor abrocitinib interruption
    Gooderham, Melinda J.
    Girolomoni, Giampiero
    Moore, Julian O'Neil
    Silverberg, Jonathan I.
    Curto, Madelyn
    Zhang, Weidong
    DiBonaventura, Marco
    Valdez, Hernan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB64 - AB64
  • [29] Janus Kinase Inhibitors in the Treatment of Atopic Dermatitis: Military Considerations
    Nolan, Colin F.
    CUTIS, 2022, 110 (06): : 316 - 320
  • [30] Efficacy of Janus kinase inhibitors in the treatment of psoriasiform atopic dermatitis
    Napolitano, Maddalena
    Foggia, Luciano
    Patruno, Cataldo
    Gallo, Lucia
    Tommasino, Nello
    Cecere, Daniele
    Megna, Matteo
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2024, 49 (10) : 1232 - 1234
12345